Systemic and intraluteal infusion of inhibin A or activin A in rhesus monkeys during the luteal phase of the menstrual cycle.
The endocrine or local actions of inhibin-related peptides synthesized by the primate corpus luteum (CL) remain undefined. This in vivo study was designed to determine whether exogenous inhibin or activin modulates pituitary gonadotropin secretion and the functional life span of the CL during the luteal phase of the menstrual cycle. Beginning at midluteal phase of the cycle, either vehicle or 1 microgram/h of recombinant human inhibin A or activin A (n = 3-6 per treatment group) was infused into rhesus monkeys via the jugular vein (i.e., peripheral infusion) or directly into the CL (i.e., intraluteal infusion) by means of an osmotic minipump for 7-14 days. Daily samples of saphenous venous serum were assayed for estradiol (E) and progesterone (P) content by RIA, and for FSH and LH levels by bioassay. Intraluteal infusion of inhibin or activin did not alter circulating P levels or the length of the luteal phase compared to those values in vehicle-infused controls. Likewise, LH levels were not different between the three groups. However, FSH levels declined progressively during inhibin infusion to 26% of pretreatment levels (p < 0.05), whereas FSH levels in vehicle-infused controls were unchanged for several days and then rose (p < 0.05) to peak levels around menses. FSH levels did not change significantly during activin infusion into the CL. Although similar results were obtained in monkeys receiving peripheral or intraluteal infusions of inhibin, events following the peripheral infusion of activin were markedly different from those during intraluteal administration.(ABSTRACT TRUNCATED AT 250 WORDS)
Stouffer
R L
RL
Division of Reproductive Science, Oregon Regional Primate Research Center, Beaverton 97006.
Dahl
K D
KD
Hess
D L
DL
Woodruff
T K
TK
Mather
J P
JP
Molskness
T A
TA
D028341:Activins; D000818:Animals; D003338:Corpus Luteum / Q000187:drug effects* / Q000502:physiology; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D007265:Inhibins / Q000008:administration & dosage / Q000494:pharmacology*; D008183:Luteal Phase / Q000187:drug effects*; D007986:Luteinizing Hormone / Q000378:metabolism; D008253:Macaca mulatta; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000097:blood; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
D011994:Recombinant Proteins; D028341:Activins; D011374:Progesterone; D004958:Estradiol; D007265:Inhibins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone